The reduction of viral replication in human immunodeficiency virus type 1 (HIV-1)-infected individuals is an important goal of chemotherapy, as the viral burden itself contributes to immune cell destruction (14, 30, 31, 41, 42) . Several clinical trials with didanosine (dideoxyinosine [ddI]) alone or zidovudine (AZT) plus ddI have shown a delay in clinical progression of disease in comparison to AZT monotherapy (12, 33) . In the clinical progression to AIDS or death, treatment with ddI alone was as effective as AZT-ddI combination therapy and superior to treatment with AZT alone (12) . Development of drug-resistant mutations to reverse transcriptase (RT) inhibitors (23, 24) or protease inhibitors (PRI) (7) has occurred during clinical trials and has been strongly associated with a poor clinical outcome in the case of AZT resistance (8) .
The ddI-related RT mutation Leu74Val, in which the Leu at position 74 is replaced by Val, confers a modest resistance (four-to sixfold) to ddI in cell culture assays and decreases AZT resistance when present in conjunction with AZT-related mutation Thr215Tyr (38) . The inhibition of RT activity by ddATP (the metabolically active moiety of ddI) can be demonstrated in cell-free assays using purified recombinant RT with a Leu74Val mutation. Enzyme kinetic studies have shown two-to sixfold increases in K i and 50% infective dose values for ddATP incorporation with purified and virion-associated mutant RTs (Leu74Val), respectively, compared to wild-type (WT) RT (27, 36) . The studies on HIV-1 RT crystal structures have shown the significant positioning of RT codon 74 on the ␤4 strand of the finger domain in the formation of the template grip that consists of portions of the p66 palm and fingers (2, 18, 21) . Further studies with HIV-1 mutant RT (Leu74Val) and synthetic templates of various lengths have shown that resistance to the dideoxynucleotide inhibitors may result from a repositioning or change in the conformation of the templateprimer that alters the ability of the enzyme to select or reject an incoming deoxynucleoside triphosphate (5) .
The detection of the Leu74Val mutation in viral populations during clinical trials is infrequent. Some researchers have detected Leu74Val during clinical trials of ddI (15, 34) , although others did not observe this mutation in subjects receiving AZTddI combination therapy (16, 22, 35) . While viral gene mutations have been primarily examined in the context of drug resistance, certain mutations may concurrently alter viral enzymes (RT and protease), resulting in a replication disadvantage for the virus (6) . The goal of this study was to determine the effect of the ddI-selected RT mutation Leu74Val on viral replication. We demonstrate that the mutation Leu74Val confers a replication disadvantage and a loss of fitness to the virus in peripheral blood mononuclear cells (PBMC) in the absence of drug.
(Part of this research was presented at the Third and Fourth Conferences on Retroviruses and Opportunistic Infections in January 1996 and January 1997, respectively, in Washington, D.C.)
Attenuated replication of cloned HIV containing ddI-selected mutation Leu74Val. Three HIV variants, Leu74Val, Lys70Arg, and Lys70Thr, were constructed in pNL4-3 (a proviral clone [contributed by M. Martin] obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases) via oligonucleotide-based mutagenesis. To create specific point mutations in the RT gene in a pNL4-3 background, site-directed mutagenesis was carried out with an Altered Sites in vitro mutagenesis system (Promega, Madison, Wis.) as described elsewhere (36) . To obtain RT variants Lys70Arg and Leu74Val, the mutagenic oligonucleotides 5ЈTTTTCTCCATCTAGTAC TGTC3Ј and 5ЈGAAATCTACTACTTTTCTCCAT3Ј, respectively, which contain point mutations, were used. The RT vari-ant Lys70Thr was generated with an oligonucleotide degenerated (for a different purpose) at codon 70; its sequence was 5ЈCTAATTTTCTCCAKDBAGTACTGTCTTT3Ј (where K ϭ T or G; D ϭ T, A, or G; and B ϭ G, T, or C). The oligonucleotide sequences described here and elsewhere in this study were derived from published sequences of proviral clone pNL4-3 (1). To generate virus, phytohemagglutinin-stimulated PBMC (5 ϫ 10 6 ) were harvested, washed twice with cold phosphate-buffered saline, and suspended in 250 l of cold medium (RPMI 1640) supplemented with fetal bovine serum and antibiotics. Five to ten micrograms of plasmid DNA was added to the cells in a cuvette (0.4 m), which was kept on ice, and the cells were transfected by electroporation at 250 V and 960 F with a Bio-Rad Gene Pulser. The electroporated cells (kept on ice) were resuspended in 5 ml of RPMI 1640 medium supplemented with fetal bovine serum and antibiotics and then incubated at 37°C under an atmosphere of 5% CO 2 . Virus production was monitored by determining the presence of antigen p24 with an enzyme-linked immunosorbent assay kit (DuPont) and by assaying for RT activity by using an in vitro RT assay (9) . Once sufficient virus production (Ͼ20 ng of p24 antigen per ml) was achieved, the cell-free virus stock supernatant was saved for assays of replication kinetics and infected cell pellets were saved to reconfirm the presence of an inserted mutation(s) in the proviral DNA.
Three independent assays of replication kinetics were carried out during this study, and Fig. 1 shows a representative example. Initial input virus concentrations were normalized in one of three ways, on the basis of equivalent RT activities (in counts per minute per milliliter), antigen p24 concentrations (in nanograms per milliliter), or 50% tissue culture infective dose (TCID 50 ) values. Since drug-resistant RT variants would be expected to have a replication advantage in the presence of the drug, it is difficult to compare the replicative capacity of WT virus with those of RT variants. Therefore, we selected two RT variants, Lys70Thr and Lys70Arg, as controls for comparison of the replication efficiencies of Leu74Val and the WT virus. The replication efficiencies of variants Lys70Thr and Leu74Val are decreased, while the Lys70Arg variant replicates as efficiently as WT (pNL4-3) virus (Fig. 1) . The kinetics of replication were determined using two separate markers (RT activity and p24 antigen concentration), and it was revealed hat the HIV variants Leu74Val and Lys70Thr replicated less efficiently than the WT and the AZT-associated variant Lys70Arg. Lys70Arg virus replicated slightly more efficiently than WT virus in three independent assays of kinetics. To ensure that the desired mutations were retained by HIV variants during replication in drug-free medium, the entire RT gene (1.7 kb) was amplified from 1 g of cellular genomic DNA by PCR using primers described elsewhere (23, 36) . PCR products were gel purified and sequenced using RT primers 5ЈTGCACTTTAAATTTTCCCATT3Ј (nucleotides 2535 to 2555), 5ЈACAATGGCCATTGACAGAAG3Ј (nucleotides 2615 to 2634), and 5ЈAAGTATACTGCATTACCATACCTA GTATA3Ј (nucleotides 2925 to 2954). Sequence analysis revealed that all the respective point mutations were retained during this period (data not shown). In one independent assay of replication kinetics, however, the HIV variant Leu74Val replicated with an efficiency similar to that of the WT (pNL4-3) virus at the input virus concentration of 1,000 TCID 50 /10 6 cells (data not shown). Nucleotide sequence analysis of the RT gene of the progeny virus revealed a reversion of the mutated codon Val-74 (GTA) to Leu (CTA). The revertant used a different triplet codon (CTA [Leu] instead of the TTA [Leu] used in the WT virus], excluding the possibility of contamination (data not shown). The reversion occurred in only 7 days of culture, indicating that reversion can occur rapidly and that the defect in the replication of variant Leu74Val is independent of the vector background.
Reversion of Val-74 to Leu at a threshold ratio of virus to cells.
To analyze whether the reversion at codon 74 was reproducible or was an isolated event, the use of the AIDS Clinical Trials Group (ACTG) protocol for determination of TCID 50 values was extended (19) to the analysis of reversion of mutated RT codon 74 (GTA). Sequence analysis of genomic DNA isolated from infected PBMC at day 7 showed that while the mutation to GTA at codon 74 was retained in lower virus dilutions (1:16, 1:64, and 1:256), a mixture of WT (TTA) and mutated (GTA) codons appeared in a higher dilution (1:1,024) of the virus stock supernatant. In an even more dilute solution (1:4,096) there was an equal mixture of GTA and TTA codons, and only the WT (TTA) codon was present in the highest dilution (1:16,384) ( Table 1 ). This indicates that reversion at codon 74 occurs preferentially in a more dilute virus pool. In contrast, the Lys70Arg mutation was retained at all dilutions of the viral stock supernatant. These observations indicate that the Leu74Val mutation is deleterious to HIV RT, possibly due to a resultant decrease in RT stability, and is capable of reverting back to the WT form, particularly when the virus concentration in the PBMC is low. The rapid reversion of the Leu74Val variant in drug-free medium provides an explanation for previous observations of the rare occurrence of the Leu74Val mutation in post-ddI therapy isolates (16, 22, 35) , which are generally propagated by cocultivation of a patient's blood with healthy donor PBMC in drug-free medium for 3 to 4 weeks before PCR analysis is performed to detect the presence of mutations. It is possible that other drug-selected mutations would also go undetected. These observations have implications with regard to monitoring the development of drug-related mutations during clinical trials.
Stock supernatants of the Leu74Val variant carry a viral pool which is inefficient in replication. The same viral stock supernatant had been used for the determination of RT activ- 6 PBMC. In each case, 8 ϫ 10 6 PBMC were infected for 1 h. Aliquots (1.2 ml) of culture supernatants were collected every day until day 7 to monitor viral replication, and equivalent amounts of RPMI 1640 were added to the cultures to replace the volumes of supernatant removed. Duplicate cell-free virus culture samples were saved to measure RT activity (data not shown) and antigen p24 concentration. This plot is representative of at least three separate assays of replication kinetics performed with input virus normalized on the basis of equivalent RT activities, antigen p24 concentrations, and TCID 50 values.
ity, p24 antigen concentrations, and TCID 50 values and therefore we compared the ratios of TCID 50 per milliliter to nanograms of p24 antigen per milliliter and of TCID 50 per milliliter to counts per minute of RT activity per milliliter. Lower ratios were obtained for HIV variants Leu74Val and Lys70Thr, indicating the presence of a viral pool which replicates inefficiently (Table 2 ). This may explain the differences in viral replication shown in Fig. 1 , and it suggests that even in the presence of a viral inoculum normalized on the basis of equivalent TCID 50 values, evolution of a viral pool which replicates inefficiently occurs in the case of variants Leu74Val and Lys70Thr. The Lys70Arg variant had TCID 50 /p24 antigen and TCID 50 /RT activity ratios which were actually higher than those of the WT (pNL4-3) virus, suggesting that it replicates slightly more efficiently than the WT. The Leu74Val mutant had lower TCID 50 /p24 antigen and TCID 50 /RT activity ratios than the Lys70Thr mutant, suggesting that Leu74Val replicated less efficiently than the Lys70Thr variant.
We further analyzed two post-ddI therapy clinical isolates from one patient who was initially treated with AZT. The RT genes of both of these isolates have been sequenced previously (36) . The first isolate, A8, obtained after 8 weeks of ddI therapy, contained a mixture of WT and mutant (Thr215Tyr) codons 215 and a WT codon 74. The second isolate, A72, obtained after 72 weeks of ddI therapy, had mutations Leu74Val and Thr215Tyr. The studies of replication kinetics of A8 and A72 showed that the latter had a replication disadvantage in drug-free medium, similar to the cloned virus with the Leu74Val mutation (data not shown). These observations further substantiate our conclusion that the inefficient replication of Leu74Val mutants in cloned virus is due to the RT mutation and not to an effect of the vector background. While these results are in agreement with the results of cloned Leu74Val virus, the replication kinetics of uncharacterized clinical isolates should be interpreted with caution due to the possible role of a mutation(s) outside of the RT coding region. The replication disadvantage for the clinical isolates with both Leu74Val and Thr215Tyr was suggested in earlier studies (37) but is directly demonstrated in the present study. This also suggests that the Leu74Val mutation makes a virus replicate more slowly than an isolate from the same patient containing Thr215Tyr alone and provides an alternative explanation for the apparent enhanced sensitivity of an AZT-resistant virus possessing a Thr215Tyr mutation and a Leu74Val mutation (38) . Our observations also suggest a mechanism for the decline in the development of an AZT-related mutation(s) during clinical trials with AZT-ddI combination therapy. This is probably due to the presence of a slowly replicating viral pool containing mutation Leu74Val, with or without Thr215Tyr, or probably other AZT-related mutations in the presence of Leu74Val. Analysis of clinical isolates from the ACTG 116A study has shown that the acquisition of a mutation at RT codon 215 or 74 is associated with a subsequent increase in the HIV RNA level, but this association is not statistically significant (43) . The reasons for this are unclear, but the real possibility of a growth advantage for the mutant viruses in the presence of the drug and other unscreened compensatory mutations, including those which may have decreased the ddI susceptibility in the latter study (116A), cannot be excluded. Other mutations in RT as well as in the protease coding sequence are known to compensate for the replication disadvantage conferred by specific mutations (17, 26) .
Loss of fitness (11%) for the variant with the Leu74Val mutation in a single passage in growth competition assays. Growth competition assays were performed by coinfecting PBMC with equivalent amounts (TCID 50 ) of two viruses and then comparing the fitness of one virus to that of the other over a period of time. This was done by monitoring the extent of virus replication as determined by the presence of a mixture of nucleotides (codons) at a single locus. In this study, the RT gene was monitored for the presence of a mixture of mutant (G) and WT (T) nucleotides at codon 74. The less fit virus will show a decrease in peak height over a period of time (Fig. 2) . To calculate the loss of fitness, the percentages of the relative peak heights of the two nucleotides were determined at various time points and the selection coefficient (s, or fitness difference) was determined by the mathematical model s ϭ 1/t ln[q(t)p(0)/p(t)q(o)], where t is the total time of passage, q(t) is the proportion of the more fit population, p(t) is the proportion of the less fit population at time t, and p(0) ϭ q(0) ϭ 0.5, the proportions of p and q at time 0 (11, 29) . To analyze the relative fitness of the mutant viruses, growth competition assays were performed (Fig. 2) by coinfecting PBMC with 500 TCID 50 of each HIV variant, as follows: WT plus Leu74Val (assay A), Lys70Arg plus Leu74Val (assay B), Lys70Thr plus Leu74Val (assay C), and WT plus Lys70Arg (assay D). The RT gene was PCR amplified and sequenced with an automated DNA sequencer (ABI370A). A 514-bp RT fragment flanking codon 74 was amplified with RT primers 5ЈGACAGTATGA TCAGATACTC3Ј (nucleotides 2422 to 2441) and 5ЈTGCA GTATACTTCCTGAAGTC3Ј (nucleotides 2936 to 2916). To normalize the concentrations of target molecules in growth competition assays, equivalent amounts (250 ng) of gel-purified PCR products were used for sequence analysis. In com- a Stock supernatants of variants Lys70Arg and Leu74Val were diluted in triplicate in RPMI 1640 medium in a 96-well plate, and equivalent amounts of phytohemagglutinin-stimulated PBMC were added to each well. The plate was incubated at 37°C in the presence of 5% CO 2 for 7 days. On day 7, the cells for each dilution were pooled and washed twice with phosphate-buffered saline, and the genomic DNA was isolated. The RT fragment flanking codons 70 and 74 was PCR amplified and purified from the gel, and equivalent amounts of target molecules (250 ng) were sequenced with an ABI373A sequencer. Percentages of peak heights were calculated from the chromatogram. A complete reversion of GTA to TTA (codon 74) was observed at a dilution of 1:16,384. a All the values were obtained from a single viral stock supernatant of each HIV variant. RT activity was determined by using the template-primer poly(U)-oligo(dT) and the substrate [methyl-3 H]TTP. Antigen p24 concentration was determined with an enzyme-linked immunosorbent assay kit (DuPont). The TCID 50 values were determined by using ACTG virology protocols and the Spearman-Karber method as described elsewhere (19) . petition assays A and B, we observed a decrease in peak size in the chromatogram for mutated codon 74 (GTA) in comparison to that of the WT codon (TTA) of pNL4-3 and Lys70Arg viruses between days 8 and 12 (Fig. 2) . The loss of fitness for mutated codon GTA (or Leu74Val) was between 11 and 12% at 12 days. In competition assay C, the loss of fitness for Leu74Val was 11% as early as day 4 and persisted at day 12. This decrease in fitness for replication provides quantitative documentation that the Leu74Val mutation results in a virus which will quickly become a minority population in relation to the WT virus. This provides strong evidence for an attenuation in replication by a ddI-selected HIV variant. In competition assay D, an equivalent mixture of AGA (Lys70Arg) and AAA (WT) codons in the day 12 genomic DNA was observed, although the peak for AGA was higher than that for the AAA codon in samples from days 4 and 6 (data not shown).
Recently, the (Ϫ)-2Ј-deoxy-3Ј-thiacytadine (3TC)-selected mutation Met184Val in an HXB2 background has been shown to marginally decrease the replicative capacity of the virus in activated PBMC over a period of 35 days (3). The difference between WT and mutant (Met184Val) virus was not striking, however, compared to the replication disadvantage observed 6 PBMC were infected for 1 h and infections were then interrupted by the addition of 10 ml of RPMI 1640. Infected PBMC were centrifuged at 450 ϫ g for 10 min and resuspended in 14 ml of fresh RPMI 1640. In a 24-well plate, infected cells were seeded at 2 ϫ 10 6 /well and incubated at 37°C in the presence of 5% CO 2 . Every 48 h, cells from each well were harvested and genomic DNA was isolated for PCR. The RT region flanking codon 74 was amplified by PCR and sequenced with an automated DNA sequencer (ABI373A). The mixture of G (GTA, 74Val) and T (TTA, 74Leu) was observed at various time points. The percentage of peak height at the G nucleotide in the chromatogram was compared with that of the T nucleotide, and the loss of fitness for variant Leu74Val was calculated by a mathematical model described elsewhere (11, 29) . An equivalent mixture of G and T is indicated by the letter N. The loss of fitness of Leu74Val was more rapid in coinfection assays with Lys70Thr than in those with the WT and the Lys70Arg variant. ND, not detected.
with the ddI-selected Leu74Val virus. The major difference between the selections of ddI-related mutation Leu74Val and the 3TC-related mutation Met184Val is the remarkably consistent selection of the latter mutation during clinical trials. In contrast, the selection of Leu74Val during clinical trials appears to be rare and requires a prolonged treatment period (16, 22, 35) . Moreover, the virus containing Leu74Val conferred a loss of fitness (11% in one passage) and reverted back to WT in 1 week in activated PBMC. This is strong evidence for a drug-selected mutation conferring a two-to threefold replication disadvantage (Fig. 1) in 7 days and a loss of fitness (11%) in a single passage. In contrast to this, AZT-related mutations appear to be more stable and have been shown to be present in drug-free cultures for over 2 months (10, 28) . Recently, one AZT-related mutation, Leu210Trp, that appears after prolonged therapy has been shown to confer a replication disadvantage to the virus (13) .
Our study provides the first evidence that the ddI-selected RT mutation Leu74Val in a pNL4-3 background confers a significant replication disadvantage and a loss of fitness to the virus in the absence of drug. We have also demonstrated that under natural selection in the absence of drug, the mutant codon Val-74 reverts back to the WT codon (Leu). This suggests that HIV-1 RT containing the mutation Leu74Val is unstable and that the WT codon, Leu-74, is preferable for optimal biological activity of RT. Reversion of single-nucleotide changes which attenuate replication in HIV-1 and simian immunodeficiency virus has been reported previously (20, 32) . The rapid reversion of this drug-resistant mutant in tissue culture extends the observation that HIV-1 is able to rapidly mutate in tissue culture and supports the recent direct documentation that HIV-1 can rapidly develop single point mutations in the envelope gene to form mutants which escape the control of cytotoxic T lymphocytes in infected patients (4) . If our in vitro findings predict the in vivo observations, this study suggests a mechanism for the improved clinical benefits observed in patients treated with ddI monotherapy and supports the hypothesis proposed by Coffin that a drug-selected mutation confers a partial replication disadvantage associated with greater clinical benefits (6) . Recent studies have shown the enormous replicating capacity of HIV-1 and estimated the production of 10 10 virions per day (31) . In another important observation on HIV-1 RT fidelity, the forward mutation rate was calculated to be 3.4 ϫ 10 Ϫ5 mutations per base pair per cycle in a single cycle of HIV-1 replication (25) . Thus, a slowly replicating virus with a Leu74Val mutation should exhibit decreased virion production and a viral population with less variation, leading to a better immune response.
Several alternative explanations suggest limitations for the clinical benefits observed with AZT-ddI combination therapy. During such therapy, AZT resistance mutations may occur, cross-resistance to ddI and/or ddATP may develop, and the Leu74Val mutation may occur less frequently or not at all. Other studies have shown the effectiveness of promising drugs, such as 3TC (39, 40) and PRI (7), in sustained suppression of the virus load for a prolonged period of time even in the presence of drug-related mutations. Combination therapy with ddI and other drugs may result in a greater clinical benefit if the replication disadvantage conferred by Leu74Val is retained in the presence of other mutations. These findings provide a mechanism of selecting for HIV variants with a replication disadvantage and suggest strategies for better use of antiviral therapies.
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